AIDS Clinical Trials Group Longitudinal Linked Randomized Trials (ALLRT): Rationale, Design, and Baseline Characteristics
- 1 August 2008
- journal article
- research article
- Published by Taylor & Francis Ltd in HIV Research & Clinical Practice
- Vol. 9 (4), 269-282
- https://doi.org/10.1310/hct0904-269
Abstract
Purpose: ALLRT is a longitudinal cohort study of HIV-infected subjects prospectively randomized into selected clinical trials for antiretroviral (ARV) treatment-naïve and ARV treatment-experienced individuals conducted by the AIDS Clinical Trials Group (ACTG). We describe the rationale, design, and baseline characteristics of the ALLRT cohort and its potential to address important research questions related to ARV therapy. Method: Standardized visits occur every 16 weeks to evaluate long-term clinical, virologic, and immunologic outcomes associated with ARV treatment. Results: A total of 4,371 subjects enrolled in ALLRT from January 2000 through June 2007. Of these, 3,146 (72%) were ARV naïve at parent study entry (18% female, 44% white, 32% black, 21% Hispanic; median age 37 years, CD4 count 218 cells/μL, follow-up 3.6 years; 343 [11%] followed ⩾8 years) and 1,225 (28%) were treatment experienced (13% female, 59% white, 20% black, 17% Hispanic; median age 42 years, CD4 count 325 cells/μL, follow-up 5.7 years). Conclusions: ALLRT provides the opportunity to understand long-term ramifications of therapeutic ARV choices and determine whether these vary by treatment regimen, timing of treatment initiation, or treatment changes over long-term follow-up. Investigations based on uniform data and specimen collection in the context of randomized ARV treatments will be critical to developing more successful long-term therapeutic strategies for HIV treatment.Keywords
This publication has 41 references indexed in Scilit:
- Suppression of HIV-1 replication by antiretroviral therapy improves renal function in persons with low CD4 cell counts and chronic kidney diseaseAIDS, 2008
- Interval and Clinical Cohort Studies: Epidemiological IssuesAIDS Research and Human Retroviruses, 2007
- Initial Treatment of HIV Infection: Randomized Trials with Clinical End Points Are Still NeededThe Journal of Infectious Diseases, 2006
- Triple-Nucleoside Regimens versus Efavirenz-Containing Regimens for the Initial Treatment of HIV-1 InfectionNew England Journal of Medicine, 2004
- Scientific and Ethical Considerations in Trial Design for Investigational Agents for the Treatment of Human Immunodeficiency Virus InfectionClinical Infectious Diseases, 2003
- Indinavir, Nevirapine, Stavudine, and Lamivudine for Human Immunodeficiency Virus–Infected, Amprenavir‐Experienced Subjects: AIDS Clinical Trials Group Protocol 373The Journal of Infectious Diseases, 2001
- Treatment with Amprenavir Alone or Amprenavir with Zidovudine and Lamivudine in Adults with Human Immunodeficiency Virus InfectionThe Journal of Infectious Diseases, 1999
- Semiparametric Efficiency in Multivariate Regression Models with Missing DataJournal of the American Statistical Association, 1995
- Analysis of Semiparametric Regression Models for Repeated Outcomes in the Presence of Missing DataJournal of the American Statistical Association, 1995
- THE MULTICENTER AIDS COHORT STUDY: RATIONALE, ORGANIZATION, AND SELECTED CHARACTERISTICS OF THE PARTICIPANTSAmerican Journal of Epidemiology, 1987